MEDICINOVA INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common stock · Additionalpaid-in · Accumulatedothercomprehensive · Accumulated · Totalstockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · capital · loss · deficit · equity | ||||||||
| Balance at December 31, 2021 | 49,043,246 | $49,043 | $476,788,012 | $(98,877) | $(393,061,094) | $83,677,084 | ||
| Share-based compensation | — | — | 642,522 | — | — | 642,522 | ||
| Issuance of common stock for option exercises | 3,000 | 3 | 7,917 | — | — | 7,920 | ||
| Net loss | — | — | — | — | (14,069,083) | (14,069,083) | ||
| Foreign currency translation adjustments | — | — | — | (16,408) | — | (16,408) | ||
| Balance at December 31, 2022 | 49,046,246 | 49,046 | 477,438,451 | (115,285) | (407,130,177) | 70,242,035 | ||
| Share-based compensation | — | — | 710,710 | — | 710,710 | |||
| Net loss | — | — | — | — | (8,571,516) | (8,571,516) | ||
| Foreign currency translation adjustments | — | — | — | (2,805) | — | (2,805) | ||
| Balance at December 31, 2023 | 49,046,246 | $49,046 | $478,149,161 | $(118,090) | $(415,701,693) | $62,378,424 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.